导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -12.42% | 3915/4773 |
| 近一周 | -1.97% | 985/5462 |
| 近一月 | -1.59% | 981/5421 |
| 近一季 | -2.42% | 1240/5209 |
| 近半年 | -7.42% | 3215/4920 |
| 近一年 | -17.41% | 3839/4366 |
| 近两年 | 31.52% | 2217/2954 |
| 近三年 | 31.27% | 1005/2253 |
| 成立以来 | 30.44% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-8.66% 4313/4961 |
-11.30% 4267/5312 |
- - |
- - |
| 2025 | 24.91% 1755/4813 |
18.06% 124/3635 |
1.98% 1972/4076 |
12.73% 3041/4524 |
-7.97% 3857/4813 |
| 2024 | 32.89% 80/3463 |
2.66% 735/2808 |
11.40% 30/3014 |
13.53% 2158/3129 |
2.37% 954/3463 |
| 2023 | -9.09% 1102/2656 |
0.95% 1667/2280 |
-0.28% 369/2385 |
-4.80% 1226/2515 |
-5.14% 1267/2655 |
| 2022 | -6.63% 131/2207 |
-9.22% 315/1919 |
8.56% 353/2016 |
-15.64% 1329/2113 |
12.32% 127/2208 |
| 2021 | -16.81% 1166/1822 |
3.45% 176/1255 |
-1.87% 1181/1330 |
-13.20% 1335/1466 |
-5.58% 1519/1822 |
| 2020 | -6.53% 975/1250 |
-13.04% 919/1028 |
2.74% 961/1067 |
-6.73% 1125/1164 |
12.16% 497/1184 |
| 2019 | 14.56% 697/1092 |
10.06% 719/754 |
-0.37% 257/804 |
-4.09% 760/850 |
8.93% 271/918 |
| 2018 | -7.80% 64/834 |
- - |
- - |
- - |
-8.52% 96/691 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 华宝香港大盘A VS. 长安沪深300非周期A(740101) |